SomaLogic significantly expands key strategic collaboration with Novartis
By: Colorado BioScience Association Date: 10/23/2019
Ten-year agreement with Novartis demonstrates broad and deep commitment to accelerating disease and therapeutic-specific insights based on proprietary proteomic technology Boulder, Colo., USA — SomaLo...
Learn MoreRegulatory Affairs Professionals Society (RAPS) Welcomes New RAPS Colorado Chapter
By: Colorado BioScience Association Date: 10/17/2019
Rockville, MD, USA, Oct. 17, 2019 (GLOBE NEWSWIRE) The Regulatory Affairs Professionals Society (RAPS) announced the official launch of the RAPS Colorado Chapter. The group first began as a RAPS...
Learn MoreSecurisyn Medical Receives FDA 510(k) Clearance for its SolidAIRity™ III Airway Stabilization System
By: Colorado BioScience Association Date: 10/14/2019
HIGHLANDS RANCH – October 9, 2019 – Securisyn Medical, LLC, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its SolidAIRity™ III Airw...
Learn MoreIM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures
By: Colorado BioScience Association Date: 10/09/2019
IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures Funding will Advance Lead Drug in Type 1 Diabetes and Develop HLA-Targeted Therapeutic Platform in Autoimm...
Learn MoreAmideBio Awarded SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism
By: Colorado BioScience Association Date: 09/30/2019
BOULDER, CO, September 30, 2019 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Researc...
Learn MoreGREFFEX, Inc. Awarded $18.7 Million Contract with NIH to Develop a Plug-and-Play Technology Platform to Expedite Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
By: Colorado BioScience Association Date: 09/27/2019
GREFFEX, Inc. (Aurora, CO), a Fitzsimons Innovation Community company, is a transformative leader in genetic engineering. The company was recently awarded an $18.7 million contract with the National I...
Learn MoreWeekly Policy Update: CBSA Submits Comment Letter to CMS Advocating for Patient Access to Timely Precision Diagnostic Information
By: Colorado BioScience Association Date: 09/27/2019
In July the Centers for Medicare and Medicaid Services (CMS) issued the CY 2020 Hospital Outpatient Prospective Payment System (HOPPS) Proposed Rule, which included concerning proposed revisions to th...
Learn MoreBoulder Based Edgewise Therapeutics Closes $50 Million Series B Financing
By: Colorado BioScience Association Date: 09/17/2019
Financing to Support Advancing Company’s Lead Product Candidate for Muscular Dystrophy- Boulder, Colo., (September 17, 2019) – Edgewise Therapeutics, a preclinical company developing small molecule th...
Learn MoreNymbl Science Releases Their August Update
By: Colorado BioScience Association Date: 09/09/2019
Below please find an overview of our progress for the month of August: • We continue to move forward towards closing out our round. We have about $235k remaining with 4 angel pitches lined up in the n...
Learn MoreDenver Business Journal Highlights Colorado’s Life Sciences Ecosystem and Our Leadership In Gene Editing
By: Colorado BioScience Association Date: 09/09/2019
Gene editing is becoming an increasingly common remedy for a variety of ailments, and Boulder area bioscience companies are leading those advancements. Building on research and technology originating...
Learn More